Millions rely on Medicare Part D, but many prescription drugs won't be covered in 2026. See which meds are excluded, why, and ...

A South Dakota law that prevents drug companies from restricting federal drug discounts for hospitals and other providers ...

AMGN signs a pricing deal with the Trump administration, cutting U.S. drug costs, expanding DTC access and securing tariff relief tied to domestic investment.

AbbVie and AstraZeneca both bring blockbuster drugs, deep pipelines and risks, but their growth paths, pressures and priorities now sharply diverge.

After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...

JPMorgan has identified four large-cap U.S. pharmaceutical stocks it expects to perform strongly in 2026, citing a favorable ...

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

Introduction of AVT05 supported by NHS England tender award in the United KingdomREYKJAVIK, ICELAND (December 22, 2025) - ...

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...

Now, it’s worth noting Stock Advisor’s total average return is 991 % — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...

A federal judge has allowed South Dakota’s new 340B drug‑discount law to remain in effect while a legal challenge from pharmaceutical giant AbbVie moves forward.

In 2025, the latest biosimilar policy developments included bipartisan efforts to enhance affordability and reduce barriers ...